Neumora Therapeutics
NMRA
NMRA
60 hedge funds and large institutions have $745M invested in Neumora Therapeutics in 2023 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
13% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 8
4.83% more ownership
Funds ownership: 23.84% → 28.67% (+4.8%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Holders
60
Holding in Top 10
3
Calls
$359K
Puts
$223K
Top Buyers
| 1 | +$41.7M | |
| 2 | +$12.5M | |
| 3 | +$11.5M | |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$9.19M |
| 5 |
Goldman Sachs
New York
|
+$6.37M |
Top Sellers
| 1 | -$8.3M | |
| 2 | -$3.99M | |
| 3 | -$3.88M | |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$3.62M |
| 5 |
AG
Artal Group
Luxembourg
|
-$3.07M |